PROTHENA CORPORATION PUBLIC LIMITED COMPANY Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2015-12-15: Form 8-K; Exhibit 10.1; Description EXHIBIT 10.1 PROTHENA BIOSCIENCES INC AMENDED AND RESTATED SEVERANCE PLAN.
- 2015-03-13: Form 10-K; Exhibit 10.11; Description EXHIBIT 10.11 FORM OF OPTION AWARD AGREEMENT.
| Filed | Form | Exhibit | Description |
|---|---|---|---|
| 2015-12-15 | 8-K | 10.1 | EXHIBIT 10.1 PROTHENA BIOSCIENCES INC AMENDED AND RESTATED SEVERANCE PLAN |
| 2015-03-13 | 10-K | 10.11 | EXHIBIT 10.11 FORM OF OPTION AWARD AGREEMENT |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |